NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga)
Estimated value
—
Awarded value
—
Suppliers
1
Lots
1
Published
11 Jun 2021
Description
NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga). The framework will commence on 1 June 2021 for a period of 7 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months. Total maximum framework agreement including extension options will be no more than 13 months.
Scope
- Reference
- CM/PHS/21/5642
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33651520
- Contract locations
- North East EnglandNorth West EnglandYorkshire and the HumberEast MidlandsWest MidlandsEast of EnglandLondonSouth East EnglandSouth West EnglandScotlandNorthern Ireland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Negotiated without publication of a contract notice
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded suppliers· 1 supplier
Awarded —
Other contracts from The NHS Commissioning Board (operating under the name of NHS England)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Octapharma Limited· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Octapharma - Blood Disorder Treatment products (inc Haemophilia A & B) | contract | £72k | 12 Mar 2025 |
| NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin | contract | — | 20 Jan 2025 |
| Human Derived Blood Products | contract | — | 28 Aug 2024 |
| NHS Framework - Blood Disorders including Haemophilia A and B - July 2024 | contract | — | 11 Jun 2024 |
| Octapharma Ltd - Octaplas LG | contract | £53k | 14 Jun 2023 |
| Octaplex Treatment | contract | £100k | 10 May 2023 |
| Blood product required for the treatment of TTP patients | contract | £98k | 03 Aug 2022 |
| NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B | contract | — | 04 Jul 2022 |
| Human Normal Immunoglobulin and Anti-D Immunoglobulin | contract | £64.3m | 23 Jul 2021 |
| NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin | contract | — | 22 Jul 2021 |